Trials / Active Not Recruiting
Active Not RecruitingNCT04900350
A Trial of AK117 (Anti-CD47) in Patients With Myelodysplastic Syndrome
A Phase I/II Trial of AK117 (Anti-CD47) in Patients With Higher-risk Myelodysplastic Syndrome
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 136 (actual)
- Sponsor
- Akeso · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a open label, phase I/II study. All patients are diagnosed with higher-risk MDS, Eastern Cooperative Oncology Group (ECOG) performance status 0-2. The purpose of this study is to evaluate the safety and efficacy of AK117 + azacitidine in subjects with higher-risk MDS.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AK117 | Subjects receive AK117 intravenously. |
| DRUG | Azacitidine | Subjects receive Azacitidine subcutaneously. |
Timeline
- Start date
- 2021-06-18
- Primary completion
- 2025-09-01
- Completion
- 2025-12-01
- First posted
- 2021-05-25
- Last updated
- 2025-03-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04900350. Inclusion in this directory is not an endorsement.